T 60mg

🔬 What Is Tirzepatide?

• Tirzepatide is a dual incretin receptor agonist that activates both:

  • GLP-1 receptor → reduces appetite, slows gastric emptying, improves insulin secretion.

  • GIP receptor → enhances insulin sensitivity, may reduce GI side effects of GLP-1s.

• Brand names:

  • Mounjaro → FDA-approved for type 2 diabetes (2022).

  • Zepbound → FDA-approved for chronic weight management (2023).

📊 Clinical Benefits

Type 2 Diabetes

• Lowers A1C by 2–2.5% (greater than semaglutide in head-to-head trials).

• Improves fasting glucose, post-meal glucose, and insulin sensitivity.

Obesity / Weight Loss

• In SURMOUNT trials, average weight loss at 72 weeks:

  • 5 mg → ~15%

  • 10 mg → ~19.5%

  • 15 mg → ~21%

• Some individuals lost >25% of body weight, approaching bariatric surgery outcomes.

Other Benefits (under study)

• Reduces visceral and liver fat (promising for NAFLD/NASH).

• Improves blood pressure, lipids, and markers of cardiovascular health.

• Being evaluated in cardiovascular outcomes trials and sleep apnea trials.

⚠️ Side Effects

Most common:

• Nausea, vomiting, diarrhea, constipation, decreased appetite.
  Other considerations:

• Gallbladder disease risk (like GLP-1s).

• Rare pancreatitis or GI obstruction.

• Small risk of thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2).

✅ Key Takeaways

• Tirzepatide = dual GLP-1 + GIP agonist.

• Approved as Mounjaro (T2D) and Zepbound (obesity).

• Efficacy: Among the most potent incretin therapies → up to 21% body weight loss.

• Dose: Weekly injections, titrated from 2.5 → up to 15 mg.

• Benefits: Improves weight, blood sugar, insulin resistance, liver fat, and heart health markers.

• Side effects: Mostly GI, plus potential long-term thyroid/gallbladder concerns.